These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12224668)

  • 21. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
    Patti G; Chello M; Pasceri V; Colonna D; Nusca A; Miglionico M; D'Ambrosio A; Covino E; Di Sciascio G
    J Am Coll Cardiol; 2006 Oct; 48(8):1560-6. PubMed ID: 17045888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 24. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

  • 25. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
    Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
    MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641
    [No Abstract]   [Full Text] [Related]  

  • 30. [Maintaining the full benefit of statins. Therapy start 10 years earlier?].
    MMW Fortschr Med; 2002 Aug; 144(33-34):55. PubMed ID: 12380149
    [No Abstract]   [Full Text] [Related]  

  • 31. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
    Nordøy A
    Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
    Sever PS; Poulter NR; Dahlöf B; Wedel H;
    Am J Cardiol; 2005 Sep; 96(5A):39F-44F. PubMed ID: 16126022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treating dyslipidemia with statins: the risk-benefit profile.
    Clark LT
    Am Heart J; 2003 Mar; 145(3):387-96. PubMed ID: 12660659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholesterol lowering in patients with CHD and metabolic syndrome.
    Goldstein MR
    Lancet; 2007 Jan; 369(9555):25; author reply 26-7. PubMed ID: 17208632
    [No Abstract]   [Full Text] [Related]  

  • 37. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
    Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease.
    Tekin A; Tekin G; Güzelsoy D; Kaya A; Gürel CV; Yiğit Z; Ulutin T
    Am J Cardiol; 2004 Jul; 94(2):206-9. PubMed ID: 15246903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amlodipine/atorvastatin (Caduet).
    Med Lett Drugs Ther; 2004 Jul; 46(1186):56. PubMed ID: 15237282
    [No Abstract]   [Full Text] [Related]  

  • 40. Caduet treats two cardiovascular conditions at once.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Jun; 29(6):56-7. PubMed ID: 15257126
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.